Anetumab ravtansine has promising antitumor activity in mesothelin-expressing solid tumors, such as mesothelioma, ovarian cancer, breast cancer, non-small-cell lung cancer, and pancreatic cancer [31]. The gene discussed is MSLN; the disease is pancreatic neoplasm.